Login to Your Account

Chronic Patients Await A New Drug

Vertex Phase III, HGS News Spark Ever-Busy HCV Space

By Randall Osborne

Monday, January 28, 2008
Vertex Pharmaceuticals Inc.'s unveiling last week of the Phase III program for the protease inhibitor telaprevir - the latest volley in the battle for a better hepatitis C virus therapy - brought cheers, muted somewhat by the inclusion of a 48-week treatment study, added to the larger test lasting half that long. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription